PURPOSE: This randomized, double-blind, placebo-controlled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic parameters, quality of life (QOL), and safety in anemic cancer patients receiving nonplatinum chemotherapy. The study also explored a possible relationship between increased hemoglobin and survival. PATIENTS AND METHODS: Three hundred seventy-five patients with solid or nonmyeloid hematologic malignancies and hemoglobin levels < or = 10.5 g/dL, or greater than 10.5 g/dL but < or = 12.0 g/dL after a hemoglobin decrease of > or = 1.5 g/dL per cycle since starting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n = 124) three times per week subcutaneously for 12 to 24 weeks. The primary end point was proportion of patients transfused; secondary end points were change in hemoglobin and QOL. The protocol was amended before unblinding to prospectively collect and assess survival data 12 months after the last patient completed the study. RESULTS:Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001). Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients. Although the study was not powered for survival as an end point, Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa. Adverse events were comparable between groups. CONCLUSION:Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy. Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
RCT Entities:
PURPOSE: This randomized, double-blind, placebo-controlled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic parameters, quality of life (QOL), and safety in anemic cancerpatients receiving nonplatinum chemotherapy. The study also explored a possible relationship between increased hemoglobin and survival. PATIENTS AND METHODS: Three hundred seventy-five patients with solid or nonmyeloid hematologic malignancies and hemoglobin levels < or = 10.5 g/dL, or greater than 10.5 g/dL but < or = 12.0 g/dL after a hemoglobin decrease of > or = 1.5 g/dL per cycle since starting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n = 124) three times per week subcutaneously for 12 to 24 weeks. The primary end point was proportion of patients transfused; secondary end points were change in hemoglobin and QOL. The protocol was amended before unblinding to prospectively collect and assess survival data 12 months after the last patient completed the study. RESULTS:Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001). Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients. Although the study was not powered for survival as an end point, Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa. Adverse events were comparable between groups. CONCLUSION:Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancerpatients receiving nonplatinum chemotherapy. Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
Authors: Arash Naeim; Lyssa Friedman; Kimberly B Whitlock; David J Pasta; Eric P Elkin; Deborah P Lubeck; Hema N Viswanathan; John Glaspy Journal: J Oncol Pract Date: 2009-09 Impact factor: 3.840
Authors: Fabian Finkelmeier; Dominik Bettinger; Verena Köberle; Michael Schultheiß; Stefan Zeuzem; Bernd Kronenberger; Albrecht Piiper; Oliver Waidmann Journal: Med Oncol Date: 2013-12-11 Impact factor: 3.064
Authors: Silas C Martin; Dennis D Gagnon; Lucy Zhang; Carsten Bokemeyer; Marinus Van Marwijk Kooy; Ben van Hout Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981
Authors: Bing Zhou; Jeffrey S Damrauer; Sean T Bailey; Tanja Hadzic; Youngtae Jeong; Kelly Clark; Cheng Fan; Laura Murphy; Cleo Y Lee; Melissa A Troester; C Ryan Miller; Jian Jin; David Darr; Charles M Perou; Ross L Levine; Maximilian Diehn; William Y Kim Journal: J Clin Invest Date: 2014-01-02 Impact factor: 14.808
Authors: Matti Aapro; Ivo Abraham; Carsten Bokemeyer; Heinz Ludwig; Karen Macdonald; Pierre Soubeyran; Matthew Turner Journal: Support Care Cancer Date: 2007-09-14 Impact factor: 3.603